
SCIENTISTS SEPARATED PSILOCYBIN'S BRAIN REWIRING FROM ITS HALLUCINATORY PATHWAY—IN MICE.
A circuit map hints that plasticity and hallucination may not be inseparable.
Slow work, real results. Studies, surgeries and experiments that quietly moved the odds in our favour.

A circuit map hints that plasticity and hallucination may not be inseparable.

One positron. Months of control. A new precision tool for fundamental physics.

Exercise kept the heart inside the Mars envelope.

NASA's newly launched space telescope has cleared an early commissioning test with more optical precision than its requirement demanded.

A preclinical formulation held onto its biological activity for more than two months at 37°C—and matched fresh material in mouse immune-response tests.

In a 10-person safety trial, an experimental optogenetic treatment produced clinically meaningful light-sensitivity gains in six participants. It did not restore normal sight.

The pollinators carried a precise biological treatment to as many as 88% of flowers.

Two fins. One layer of living muscle. A light to follow.

The fabric let light, rain and air through — while keeping insect mouths out.

Three remote counseling sessions and a phone tool helped young people make safer decisions in a rigorous trial.

Four weeks of at-home magnetic-field sessions produced encouraging early signals for long-COVID cognitive impairment.

A small trial suggests the first medication for lymphedema may be getting closer.

A Phase 3 trial turned the walls of a surgical cavity into the radiation treatment.

A small scheduling change produced a surprisingly large clinical difference.

A painless test using urine and a vaginal swab showed it could accurately rule out womb cancer for most women with postmenopausal bleeding.

A Cambridge-led study gave nicotinamide riboside to eight people with mitochondrial DNA disease. It was well tolerated and showed early signs of working.

In a mouse model of multiple sclerosis, the experimental drug K-9 restored function after paralysis and vision loss had already set in. It has not been tested in people with MS.

In the TESEO trial, 450 adults received different benznidazole regimens. The 30-day, once-daily option matched the standard 60-day course in the trial and caused fewer side effects.
THE SCAN CAME BACK EMPTY.
Researchers at Texas Children's, Baylor College of Medicine and Seattle Children's reported in the New England Journal of Medicine that a child with hepatoblastoma had complete regression of disease after a novel immunotherapy given as part of the CARE study.
THE HAND FELT BACK.
Seventeen years after an amputation, Alexander “Avi” Davidson became the first participant to take Utah's thought-controlled bionic arm home — with a nerve interface that gives it a sense of touch.
TWO ORIGINS. ONE BRAIN.
Stanford researchers found the forebrain/midbrain and hindbrain arise from distinct progenitor cell populations — and used that insight to grow functional human hindbrain motor neurons in the lab.
THE GENOME GOT A BIGGER TOOLBOX.
A new lab method can place gene-sized DNA at targeted sites in human cells. No patients yet.
LAB BENCH HOPE.
42 antibodies made. Two blocked the reaction. In a dish, for now.
STAGE 1 AND 2, CAUGHT ABOUT 87% OF THE TIME
An investigational blood test flagged stage 1 and 2 pancreatic cancer about 87% of the time in a study of roughly 1,800 people. Not FDA-cleared. Still a big deal.